Ivarmacitinib for moderate-to-severe atopic dermatitis
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a new oral medication called Ivarmacitinib for people with moderate-to-severe atopic dermatitis (a type of eczema). The goal is to see if it helps reduce symptoms and improve skin condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 75 years old.
- You have been diagnosed with moderate-to-severe atopic dermatitis (eczema).
- You do not have active infections like tuberculosis, hepatitis B, or hepatitis C.
- You do not have a history of blood clots or certain cancers.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- Your blood tests show normal levels of certain blood cells and hemoglobin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether switching to a new oral medication (ivarmacitinib) helps people with moderate-to-severe eczema who still have symptoms even after using a standard injectable treatment (IL-4Rα inhibitor like dupilumab) for at least 12 weeks. It aims to see if the switch is effective and safe for these patients.
This study tests a pill called Ivarmacitinib (a JAK inhibitor) for people with advanced solid tumors who had to stop immunotherapy because of side effects. The drug aims to calm the immune system and may help you restart cancer treatment.
This study tests a new pill, ivarmacitinib, for people with moderate-to-severe rheumatoid arthritis who have not gotten enough relief from standard treatments. It aims to reduce joint pain and swelling and improve daily life.
This trial tests an investigational drug, ivarmacitinib, to see if it can reduce inflammation and pain in people with polymyalgia rheumatica and help them avoid using steroids. The drug works by blocking certain immune system signals that cause joint and muscle stiffness.
This study compares a new pill (ivarmacitinib) to standard steroid treatment for people with mild-to-moderate lupus. It aims to see if the new drug can better control symptoms like joint pain and skin rashes while possibly reducing steroid side effects.
This trial is testing an oral medication called ivarmacitinib, which may help protect the insulin-making cells in your pancreas and slow down the progression of type 1 diabetes. It is designed for people who have just been diagnosed with type 1 diabetes.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.